Anthera Pharmaceuticals Inc. (NASDAQ:ANTH)’s share price shot up 4.4% on Wednesday . The stock traded as high as $3.10 and last traded at $3.08, with a volume of 443,973 shares trading hands. The stock had previously closed at $2.95.

Several brokerages recently weighed in on ANTH. Zacks Investment Research lowered Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, July 4th. FBR & Co reiterated a “hold” rating on shares of Anthera Pharmaceuticals in a research note on Monday, June 20th. Jefferies Group reiterated a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Thursday, June 30th. Finally, HC Wainwright initiated coverage on Anthera Pharmaceuticals in a research note on Friday, July 8th. They set a “buy” rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $8.70.

The firm has a 50-day moving average of $3.10 and a 200 day moving average of $3.42. The company’s market cap is $127.60 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/anthera-pharmaceuticals-inc-anth-shares-up-4-4.html

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.04. Anthera Pharmaceuticals had a negative return on equity of 131.24% and a negative net margin of 1,273.45%. On average, equities analysts predict that Anthera Pharmaceuticals Inc. will post ($1.37) earnings per share for the current year.

Large investors have recently made changes to their positions in the company. Bridgeway Capital Management Inc. acquired a new stake in shares of Anthera Pharmaceuticals during the second quarter valued at $463,000. Jefferies Group LLC acquired a new stake in shares of Anthera Pharmaceuticals during the second quarter valued at $155,000. Allianz Asset Management AG increased its stake in shares of Anthera Pharmaceuticals by 18.4% in the second quarter. Allianz Asset Management AG now owns 184,213 shares of the biopharmaceutical company’s stock valued at $569,000 after buying an additional 28,595 shares during the period. State Street Corp increased its stake in shares of Anthera Pharmaceuticals by 42.5% in the second quarter. State Street Corp now owns 792,859 shares of the biopharmaceutical company’s stock valued at $2,449,000 after buying an additional 236,552 shares during the period. Finally, ProShare Advisors LLC increased its stake in shares of Anthera Pharmaceuticals by 3.4% in the second quarter. ProShare Advisors LLC now owns 35,319 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,168 shares during the period. Institutional investors and hedge funds own 55.24% of the company’s stock.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

5 Day Chart for NASDAQ:ANTH

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.